Phinomics Unlocks Circular DNA Secrets on All Access with Andy Garcia

For decades, extrachromosomal circular DNA remained a laboratory enigma. These fragile structures hold critical instructions for how cells adapt and resist treatment, yet they were notoriously difficult to isolate without destruction. New computational tools now allow researchers to extract these circles intact, offering a clearer picture of molecular biology than previously possible.

At the heart of this shift is a fundamental disagreement over data strategy. While many models rely on sheer volume, Phinomics argues that diversity is the missing link. According to co-founder Massa Shoura, fragmented data often compounds errors. By matching data across normal and diseased states, the company aims to build explainable AI models that replace the current black-box approach to drug development.

This methodology addresses a sobering statistic: 90% of oncology drugs fail during clinical trials. By integrating distinct biological layers—including RNA, proteins, and circular DNA—researchers gain a multi-dimensional view of cellular behavior. This shift toward transparent, multi-modal modeling seeks to bridge the gap between abstract computer predictions and clinical reality, offering a pathway toward more precise therapeutic outcomes.